Figure 2. Trial profile.

All participants received 480 mg piperaquine. Twelve participants also received 960 mg piperaquine to treat recrudescence. ⁱMosquito infectivity not assessed in cohort 1 (n = 6). ⁱⁱAll 6 participants in the EFITA study were not intended to be randomized and 4 participants in the OZGAM study were not randomized due to recruitment and drug availability limitations (as detailed in Methods). ⁱⁱⁱAll 6 participants from EFITA and 2 from OZGAM did not receive any drug during the period of gametocyte carriage (Supplemental Table 1).